UniQure (QURE) rallied roughly 78% after disclosing encouraging clinical data for AMT-130, its investigational gene therapy targeting Huntington's disease, a condition with no approved disease-modifying treatment and a large unmet need. The company enters this catalytic event from a weak financial baseline — revenue of $16.1M fell 40.6% year-over-year and net margin sits at -1,236%, reflecting the cash-burn profile typical of late-stage gene therapy developers.

The immediate question is whether the data is robust enough to sustain the re-rating or whether this is a relief rally on ambiguous interim numbers. Huntington's gene therapy is a high-bar FDA area; investors should watch for a formal readout timeline, any partnership or licensing activity that would validate the program externally, and the company's cash runway against the expected development spend before commercialization.